Non-RCT finds dual stem cell treatment improves vision in patients with aniridia — Evidence Review
Published in JAMA Ophthalmology, by researchers from Moorfields Eye Hospital, University College London
Researched by
— the AI search engine for science
Table of Contents
A first-in-human trial at Moorfields Eye Hospital and University College London found that a dual stem cell treatment improved vision and ocular surface health in patients with aniridia-related keratopathy (ARK), a rare, previously untreatable cause of progressive sight loss. Related studies in the field of regenerative ophthalmology broadly support these findings, demonstrating that stem cell-based therapies can restore vision or improve ocular function in various degenerative eye conditions.
- Previous research has shown that stem cell-derived photoreceptor and retinal pigment epithelial (RPE) cell transplantation can restore visual responses and function in animal models and early human trials, indicating the potential of cellular therapies for severe eye diseases 1 2 3 4 5.
- Studies highlight the importance of cell type and delivery method: both embryonic/induced pluripotent stem cells (ESCs/iPSCs) and mesenchymal stem cells (MSCs) have shown promise, with dual or combination approaches potentially enhancing outcomes, as suggested by the new trial’s use of two stem cell types 2 4 5.
- While most related studies focus on retinal diseases, rather than corneal surface pathologies like ARK, the consensus is that stem cell treatments are generally safe and may lead to clinically meaningful improvements in vision and ocular health, though larger and longer-term trials are needed 2 3 6.
Study Overview and Key Findings
Aniridia-related keratopathy (ARK) leads to progressive corneal clouding and vision loss due to genetic defects affecting limbal stem cells at the eye’s surface. Until now, effective treatments for ARK have been lacking, with patients facing inevitable deterioration of sight. This first-in-human clinical trial is significant because it targets a rare and previously untreatable disease using an innovative dual stem cell approach, potentially opening new therapeutic avenues for similar ocular surface disorders. Unlike most prior research, which has focused on the retina, this study addresses corneal regeneration.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | Moorfields Eye Hospital, University College London |
| Journal Name | JAMA Ophthalmology |
| Authors | Abigail Eve Kaye, Louise Morgan, Radhika Shah, Amanda J. Vernon, Andrew Embleton-Thirsk, Hakim-Moulay Dehbi, Daniel Sibley, Ahmed Oreaba, Julie T. Daniels, Sajjad Ahmad |
| Population | Patients with aniridia-related keratopathy |
| Sample Size | n=9 |
| Methods | Non-randomized Controlled Trial (Non-RCT) |
| Outcome | Ocular surface score, vision test scores |
| Results | Average OSS improved from 9.4 to 5.9 after 3 months. |
Literature Review: Related Studies
To place the new findings in context, we searched the Consensus database, which contains over 200 million research papers. The following search queries were used to identify relevant literature:
- dual stem cell therapy vision restoration
- human trial stem cell outcomes
- oss score improvement vision treatment
Related Studies Table
| Topic | Key Findings |
|---|---|
| How effective are stem cell therapies for restoring vision in degenerative eye diseases? | - De novo generation and transplantation of retinal cells, including photoreceptors and RPE, can restore visual responses and function in animal models and in early-stage human trials 1 3 4 5. - ESC/iPSC-derived retinal cells and mesenchymal stem cells show promise in replacing lost cells and preserving or improving vision, though challenges remain for widespread clinical use 2 3 4 5. |
| What are the safety and feasibility outcomes of stem cell therapies in clinical trials? | - Clinical trials of mesenchymal stem cells (MSCs) and other stem cell types across various diseases report no serious adverse events and suggest good safety profiles, though most studies are small and early-phase 6 7 8 9 10. - Larger, long-term studies are needed to conclusively assess safety, efficacy, and optimal protocols 6 9 10. |
| Which cell types and delivery strategies show most potential for ocular surface or retinal repair? | - ESCs/iPSCs can generate retinal progenitor cells and photoreceptors that form new synaptic connections and integrate into host tissue, supporting vision restoration 2 4 5. - Combination approaches (e.g., dual stem cell types or scaffold delivery) may enhance outcomes by supporting both structural repair and cell survival, aligning with the dual stem cell scaffold used in the new ARK trial 2 5. |
| How do stem cell therapies compare to other vision-restoring or ocular surface treatments? | - Non-cell-based interventions, such as prosthetic ocular surface devices and interventional glaucoma treatments, can improve ocular surface scores and symptoms but do not directly address underlying stem cell deficiency or tissue regeneration 11 12. - Stem cell therapies aim to restore lost tissue and function at a cellular level, potentially offering advantages for progressive or severe diseases unresponsive to conventional treatments 2 3 4. |
How effective are stem cell therapies for restoring vision in degenerative eye diseases?
The majority of related studies indicate that stem cell-based therapies can restore vision or visual responses in animal models and in early human studies, particularly for retinal degenerative diseases. Approaches utilizing ESCs/iPSCs or MSCs to generate or replace photoreceptors, RPE, or other retinal cells have led to measurable improvements in visual function, supporting the promise of regenerative cellular therapies for blinding conditions. The new ARK trial extends this paradigm to the corneal surface, offering preliminary evidence that similar principles may apply beyond the retina.
- Stem cell transplantation has restored visual function in models of congenital blindness and advanced retinal degeneration 1 4 5.
- ESC/iPSC-derived cells and MSCs can replace lost neurons, protect endogenous cells, and support regeneration in the retina 2 3.
- Early-phase clinical studies and preclinical evidence support vision improvement following stem cell therapy, though larger human trials are still needed 3 5.
- The current ARK study is among the first to demonstrate improvement in a corneal surface disease using a dual stem cell approach, complementing existing retinal-focused research 2 5.
What are the safety and feasibility outcomes of stem cell therapies in clinical trials?
Safety is a primary concern for any new therapy. Multiple systematic reviews and clinical trials involving MSCs and other stem cell types across a range of conditions, including ophthalmic diseases, report no significant safety concerns or serious adverse events. However, most studies are small, early-phase, or lack long-term follow-up. The new ARK trial’s absence of reported serious adverse events aligns with this broader safety profile, but larger and longer-term studies will be essential to confirm these findings.
- Systematic reviews indicate broad potential for clinical use of MSCs with no serious adverse events reported to date 6 9.
- Randomized trials in stroke and COVID-19 patients reinforce the general safety and feasibility of MSC administration, with promising clinical outcomes 7 10.
- Early-phase ocular trials report positive safety outcomes, but call for more robust, controlled studies with long-term monitoring 6 9 10.
- The new ARK trial supports the pattern of favorable safety in ophthalmic stem cell therapy, but is limited by its small sample size and short follow-up.
Which cell types and delivery strategies show most potential for ocular surface or retinal repair?
Research highlights that both the choice of cell type and the delivery strategy are critical for the success of regenerative therapies. ESCs/iPSCs and MSCs each offer unique advantages: ESC/iPSC-derived retinal cells can integrate and form functional synapses, while MSCs may provide trophic support and immunomodulation. Combination or dual cell approaches, as used in the ARK trial, could further enhance outcomes by addressing multiple aspects of tissue repair. Scaffold-based delivery, which provides structure and directs cell placement, may further improve integration and efficacy.
- ESCs/iPSCs have demonstrated the ability to generate functional retinal and photoreceptor cells that restore complex visual responses 2 4 5.
- MSCs are valued for their paracrine effects, support of endogenous cell survival, and immune modulation 2 6.
- The ARK study’s use of a collagen scaffold to deliver both limbal epithelial and stromal stem cells represents a novel approach, potentially improving cell retention and integration 2 5.
- Combination strategies are increasingly seen as promising in challenging or previously untreatable conditions 2 5.
How do stem cell therapies compare to other vision-restoring or ocular surface treatments?
Non-cell-based treatments, such as prosthetic ocular surface devices and glaucoma interventions, can improve symptoms and ocular surface scores but do not address underlying stem cell loss or drive tissue regeneration. Stem cell therapies aim to restore lost cellular function and structure, potentially providing a more durable or disease-modifying benefit for progressive, severe, or refractory eye diseases. The ARK trial’s improvement in both vision and ocular surface scores suggests a level of efficacy distinct from symptom management alone.
- Prosthetic devices and surgical interventions can relieve symptoms and improve ocular surface indices, but do not regenerate lost tissue 11 12.
- Stem cell approaches may offer more comprehensive restoration by replacing or regenerating damaged cells 2 3 4.
- For rare and progressive conditions like ARK, stem cell therapies may represent the only meaningful path to improved or stabilized vision 2 5.
- The ARK trial’s dual cell scaffold strategy provides a model for potentially superior outcomes compared to existing non-regenerative options 2 5.
Future Research Questions
While the new dual stem cell therapy for ARK offers promising early results, important questions remain regarding its long-term safety, efficacy, and broader applicability. Further research is necessary to optimize cell sources, delivery strategies, and patient selection, as well as to compare this approach with other emerging regenerative and non-regenerative therapies.
| Research Question | Relevance |
|---|---|
| What are the long-term safety and efficacy outcomes of dual stem cell therapy for aniridia-related keratopathy? | Long-term data are lacking for this novel therapy, and previous reviews emphasize the need for extended follow-up to assess durability and late adverse events 6 9. |
| How does dual stem cell therapy compare to single cell-type approaches in restoring vision and ocular health? | Comparative studies could clarify whether combining multiple stem cell types offers superior outcomes, as dual or combination strategies are hypothesized to enhance repair 2 5. |
| What are the optimal cell sources and scaffold materials for corneal regeneration? | The choice of cell type and delivery matrix can significantly impact integration, survival, and function, as seen in retinal and corneal models 2 4 5. |
| Can dual stem cell therapy benefit other ocular surface or degenerative eye diseases? | Expanding this approach to other diseases could broaden its clinical impact; related studies suggest stem cell therapies may be applicable to various degenerative eye conditions 2 3 4. |
| What are the immunological challenges and requirements for successful corneal stem cell transplantation? | Understanding immune responses and mechanisms of graft integration is key for widespread clinical translation, as highlighted in retinal and corneal transplantation research 3 5. |